| Followers | 2543 |
| Posts | 250734 |
| Boards Moderated | 34 |
| Alias Born | 05/06/2014 |
Monday, February 19, 2018 1:39:09 PM
$CTRV FDA Approval CTRV
“We are very grateful the FDA supports our pursuit of the 505(b)(2) Regulatory Pathway,” said James Sapirstein, Chief Executive Officer of ContraVir. “This critical feedback will allow us to significantly shorten our non-clinical development program by at least 12-18 months, and will accelerate our clinical program towards registration.”
https://finance.yahoo.com/news/contravir-pharmaceuticals-reaches-agreement-fda-110000237.html
“We are very grateful the FDA supports our pursuit of the 505(b)(2) Regulatory Pathway,” said James Sapirstein, Chief Executive Officer of ContraVir. “This critical feedback will allow us to significantly shorten our non-clinical development program by at least 12-18 months, and will accelerate our clinical program towards registration.”
https://finance.yahoo.com/news/contravir-pharmaceuticals-reaches-agreement-fda-110000237.html
investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
